Angiotensin converting enzyme inhibitors vs angiotensin receptor blockers
Pro Research Analysisby 
Searched over 200M research papers
Comparative Effectiveness of ACE Inhibitors and ARBs for Hypertension and Cardiovascular Outcomes
Blood Pressure Control and Major Cardiovascular Events
Both angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are effective at lowering blood pressure and reducing the risk of major cardiovascular events such as heart attack, stroke, and heart failure in patients with hypertension or at high cardiovascular risk. Multiple large studies and meta-analyses have shown that both drug classes provide similar protection against these outcomes, with no significant difference in the rates of acute myocardial infarction, stroke, or heart failure between ACE inhibitors and ARBs when used as first-line therapy for hypertension 1247.
Mortality and Cardiovascular Death
Some evidence suggests that ACE inhibitors may be more effective than ARBs in reducing total mortality and cardiovascular deaths. Meta-analyses and systematic reviews have found that ACE inhibitors significantly reduce the risk of all-cause and cardiovascular death, while ARBs do not consistently show this benefit 17. However, other large real-world studies and randomized trials have found no significant difference in mortality between the two drug classes, indicating that the advantage of ACE inhibitors over ARBs for mortality may be modest or context-dependent 248.
Outcomes in Acute Myocardial Infarction
In patients with acute myocardial infarction (AMI), the evidence is mixed. Some studies report that ACE inhibitors are associated with lower rates of cardiac death, all-cause death, and recurrent MI compared to ARBs . Other large cohort studies, particularly in Asian populations, have found that ARBs may be associated with lower all-cause mortality and hospitalization for heart failure compared to ACE inhibitors, with no significant difference in major adverse cardiovascular events . In patients with MI but without heart failure, ARBs and ACE inhibitors appear to have similar effectiveness for most outcomes, though ARBs may be preferred in those intolerant to ACE inhibitors .
Safety and Tolerability
ARBs are generally better tolerated than ACE inhibitors. Patients taking ARBs experience fewer withdrawals due to adverse effects, mainly because ACE inhibitors are more likely to cause dry cough and, less commonly, angioedema. This improved tolerability can lead to better medication adherence with ARBs 248.
Special Populations and Additional Benefits
Both ACE inhibitors and ARBs are beneficial in patients at high risk for atherosclerotic disease, even if they are normotensive, reducing the risk of cardiovascular death, non-fatal MI, and stroke . Both drug classes also reduce the risk of new-onset diabetes, with similar effectiveness 710.
Recent Large-Scale and Regional Studies
Recent large-scale studies from China and Taiwan suggest that ARBs may be associated with lower all-cause and cardiovascular mortality compared to ACE inhibitors in real-world practice, especially in patients with well-controlled or newly diagnosed hypertension 69. However, these findings may be influenced by regional prescribing patterns, patient characteristics, and healthcare systems.
Conclusion
ACE inhibitors and ARBs are both effective for lowering blood pressure and preventing major cardiovascular events. ACE inhibitors may offer a slight advantage in reducing total and cardiovascular mortality, but ARBs are better tolerated and may be preferred for patients who experience side effects with ACE inhibitors. In practice, the choice between these drug classes should consider individual patient risk factors, comorbidities, and tolerability, as both provide substantial cardiovascular protection 1245+5 MORE.
Sources and full results
Most relevant research papers on this topic